AveXis (AVXS) Receives News Impact Rating of 0.16

News headlines about AveXis (NASDAQ:AVXS) have trended somewhat positive on Sunday, according to Accern. The research firm identifies negative and positive news coverage by monitoring more than 20 million news and blog sources in real time. Accern ranks coverage of public companies on a scale of negative one to one, with scores nearest to one being the most favorable. AveXis earned a media sentiment score of 0.16 on Accern’s scale. Accern also gave media stories about the company an impact score of 45.6062907805975 out of 100, meaning that recent news coverage is somewhat unlikely to have an impact on the stock’s share price in the near term.

Several equities analysts have recently weighed in on the company. BidaskClub raised AveXis from a “sell” rating to a “hold” rating in a research report on Thursday. Canaccord Genuity set a $110.00 target price on AveXis and gave the company a “hold” rating in a research report on Wednesday. Citigroup boosted their target price on AveXis from $100.00 to $116.00 and gave the company a “buy” rating in a research report on Monday, October 2nd. BMO Capital Markets reissued an “outperform” rating and set a $123.00 target price on shares of AveXis in a research report on Saturday, September 30th. Finally, UBS Group reissued a “buy” rating and set a $122.00 target price (up previously from $95.00) on shares of AveXis in a research report on Tuesday, October 3rd. Three equities research analysts have rated the stock with a sell rating, four have issued a hold rating and thirteen have assigned a buy rating to the company’s stock. The company has an average rating of “Buy” and an average price target of $110.67.

Shares of AveXis (AVXS) traded up $2.52 during trading on Friday, reaching $109.15. The company’s stock had a trading volume of 287,838 shares, compared to its average volume of 374,783. The company has a market cap of $3,570.00 and a P/E ratio of -19.56. AveXis has a 12 month low of $46.41 and a 12 month high of $109.60.

AveXis (NASDAQ:AVXS) last announced its quarterly earnings data on Thursday, November 9th. The company reported ($1.52) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of ($1.48) by ($0.04). During the same quarter in the prior year, the company earned ($0.87) earnings per share. equities analysts forecast that AveXis will post -6.19 EPS for the current fiscal year.

In other news, VP Andrew F. Knudten sold 2,000 shares of the stock in a transaction on Monday, December 4th. The stock was sold at an average price of $94.48, for a total transaction of $188,960.00. Following the transaction, the vice president now owns 7,000 shares of the company’s stock, valued at approximately $661,360. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Also, insider Brian K. Kaspar sold 15,000 shares of the stock in a transaction on Monday, October 9th. The stock was sold at an average price of $101.46, for a total value of $1,521,900.00. The disclosure for this sale can be found here. Insiders sold a total of 52,340 shares of company stock worth $5,172,298 in the last ninety days. 18.60% of the stock is currently owned by corporate insiders.

ILLEGAL ACTIVITY NOTICE: This piece was originally posted by Community Financial News and is owned by of Community Financial News. If you are reading this piece on another publication, it was copied illegally and republished in violation of US & international copyright and trademark laws. The legal version of this piece can be read at https://www.com-unik.info/2017/12/24/avexis-avxs-receives-news-impact-rating-of-0-16.html.

AveXis Company Profile

AveXis, Inc is a clinical-stage gene therapy company. The Company operates through the developing and commercializing gene therapy treatments for patients suffering from neurological genetic diseases segment. The Company’s product candidate, AVXS-101, is its gene therapy product candidate that is in a Phase I clinical trial for the treatment of spinal muscular atrophy (SMA) Type 1, which is a genetic disorder characterized by motor neuron loss and associated muscle deterioration.

Insider Buying and Selling by Quarter for AveXis (NASDAQ:AVXS)

Receive News & Ratings for AveXis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AveXis and related companies with MarketBeat.com's FREE daily email newsletter.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit